Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| AHMA | Ambitions Enterprise Management L.l.c | $2.23 | -$2.32 | -50.93% | 1.5M | $134M | $1.10$39.50 |
| VALN | Valneva Se | $6.50 | -$3.82 | -37.02% | 28.4K | $888M | $5.43$12.25 |
| AREB | American Rebel | $6.46 | -$2.75 | -29.86% | 74.9K | $69M | $6.20$835,600.00 |
| WSHP | WeShop | $8.36 | -$3.31 | -28.36% | 34.6K | $274M | $7.21$250.00 |
| SWMR | Swarmer | $26.64 | -$10.07 | -27.43% | 4.5M | $453M | $5.00$65.04 |
| ANNA | AleAnna | $5.39 | -$1.68 | -23.76% | 187.6K | $287M | $2.31$18.30 |
| ATLN | Atlantic International | $3.71 | -$0.74 | -16.63% | 159.8K | $279M | $1.16$6.10 |
| ACXP | Acurx Pharmaceuticals | $4.72 | -$0.88 | -15.71% | 565.7K | $16M | $1.33$21.00 |
| ROMA | Roma Green Finance | $5.85 | -$1.09 | -15.71% | 372K | $413M | $0.72$8.88 |
| CODX | Co-Diagnostics | $2.19 | -$0.40 | -15.61% | 991.2K | $5.4M | $2.05$46.50 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $25.08 | -$3.70 | -12.86% | 2M | - | $19.91$75.28 |
| NERV | Minerva Neurosciences | $6.61 | -$0.93 | -12.33% | 14.4K | $326M | $1.15$12.46 |
Related Articles
Featured Article
Thinking About Buying Swarmer After Its Explosive IPO? Here Are 3 Things Investors Need to Know.
Jack Delaney|Mar 21, 2026
Don't let the fear of missing out drive your investing decision.
Is This New Data on Valneva's Less-Effective Booster Concerning?
Keith Speights and Brian Orelli, PhD|Dec 18, 2021
Some recent dismal results for Valneva's vaccine looked bad. But there could be more to the story.
2 Stocks That Could Soar With the Emergence of the Omicron Variant
Keith Speights and Brian Orelli, PhD|Dec 12, 2021
It's too soon to know what the full impact of omicron will be. But these vaccine makers could be particular winners.
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
Dan Caplinger|Oct 18, 2021
The Nasdaq looks poised to open slightly lower after a strong week.
Co-Diagnostics: Buy the Dip?
Cory Renauer|Mar 29, 2021
Analysts following this coronavirus stock have darkened their post-pandemic outlook.
What Investors Didn't Like About Co-Diagnostics' Q4 Update
Keith Speights|Mar 26, 2021
The company missed earnings expectations and hinted at slowing growth in 2021.
Co-Diagnostics Names New CFO and CSO
Eric Volkman|Feb 23, 2021
With the latter appointment, the company's founder moves into a more advisory role.
Up 938% in 2020, Is Co-Diagnostics Still a Buy in 2021?
Taylor Carmichael|Jan 30, 2021
This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.
Forget Snowflake! Buy This Ultra-High-Growth Stock
Jason Hawthorne|Jan 15, 2021
This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
These Were the 3 Best Coronavirus Stocks of 2020
Keith Speights|Jan 1, 2021
Not all of them were COVID-19 vaccine makers.
